[starratingmulti id=1 tpl=12]
In the prescription obesity drug world, Acomplia is a player that is available in Europe under its generic name, Rimonabant, as well as under the name Zimulti. It first received its approval within those nations in 2006. It has not, however, received approval from the FDA and is, therefore, not available in the United States. The drug falls within a class of drugs that is relatively new to the diet industry when compared to the other options currently in the prescription drug marketplace.
This type of drug class is known as the Cannabinoid-1 Receptor Blocker therapeutic agents. Though it is also suspected that Acomplia may have uses in assisting smokers to quit the habit, it has not yet received any official approvals for that purpose. Drugs within this class function by blocking the brain and organ Cannabinoid-1 Receptors. This is believed to help to boost the metabolism as well as to create an appetite suppression effect.
The result is, therefore, a reduction in food cravings as well as in the amount of food that is consumed every day, as well as a better metabolism of the foods that are consumed, so that there is less likelihood of fat storage based on what is eaten. When combined with a healthy, low calorie diet, and proper exercise, Acomplia can help the dieter to reduce excess fat on the body more easily. This drug is prescribed alongside those two lifestyle changes as it will not cause weight to be lost on its own.
Some studies have shown that Acomplia diet pills may be a part of a helpful program in the prevention of some forms of cardiovascular disease. In the countries where this drug has been approved for sale, it is considered to be safe for use by patients who are fighting obesity and who have already been diagnosed with Type 2 diabetes.
Common side effects that have been noted within clinical trials of Acomplia diet pills include nausea and vomiting. These studies showed that those who took the drug experienced highly varied and inconsistent results. Among them, 19 percent also experienced negative side effects of one kind or another. Moreover, there is strong evidence to suggest that this drug is not safe for individuals who are also suffering from depression, as trials have indicated that it can significantly worsen this condition.
As Acomplia remains a relatively new drug, it continues to be studied and the results of its use among patients who are prescribed this medication continue to be monitored.
{ 0 comments… add one now }